Octreotide Therapy for the Sjögren Syndrome
2002; American College of Physicians; Volume: 137; Issue: 9 Linguagem: Inglês
10.7326/0003-4819-137-9-200211050-00031
ISSN1539-3704
Autores Tópico(s)Ophthalmology and Eye Disorders
ResumoLetters5 November 2002Octreotide Therapy for the Sjögren SyndromeTri G. Phan, FRACP, FRCPA, Tom P. Gordon, FRACP, FRCPA, PhD, Martin H.N. Tattersall, FRACP, MD, and Robert H. Loblay, FRACP, PhDTri G. Phan, FRACP, FRCPARoyal Prince Alfred Hospital; Camperdown, NSW 2050, AustraliaFlinders Medical Centre and Flinders University; Bedford Park, SA 5042, AustraliaUniversity of Sydney; Newtown, NSW 2006, AustraliaSearch for more papers by this author, Tom P. Gordon, FRACP, FRCPA, PhDRoyal Prince Alfred Hospital; Camperdown, NSW 2050, AustraliaFlinders Medical Centre and Flinders University; Bedford Park, SA 5042, AustraliaUniversity of Sydney; Newtown, NSW 2006, AustraliaSearch for more papers by this author, Martin H.N. Tattersall, FRACP, MDRoyal Prince Alfred Hospital; Camperdown, NSW 2050, AustraliaFlinders Medical Centre and Flinders University; Bedford Park, SA 5042, AustraliaUniversity of Sydney; Newtown, NSW 2006, AustraliaSearch for more papers by this author, and Robert H. Loblay, FRACP, PhDRoyal Prince Alfred Hospital; Camperdown, NSW 2050, AustraliaFlinders Medical Centre and Flinders University; Bedford Park, SA 5042, AustraliaUniversity of Sydney; Newtown, NSW 2006, AustraliaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-9-200211050-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: The Sjögren syndrome is a systemic autoimmune disease characterized by focal lymphocytic infiltration and exocrine gland destruction. Therapy for the Sjögren syndrome has been disappointing and limited to provision of artificial tears and prevention of ocular and oral complications (1). No treatment both downmodulates inflammation and reverses exocrine dysfunction.Case Report: A 72-year-old woman had primary Sjögren syndrome that had been diagnosed 17 years earlier when she presented with excessive fatigue, the Raynaud phenomenon, and ocular and oral symptoms. Ocular symptoms included dry eyes, a sensation of gravel in the eyes, and intolerance of air conditioning. ...References1. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12:391-8. [PMID: 10990175] CrossrefMedlineGoogle Scholar2. Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, Hofland LJ. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol. 2000;143 Suppl 1 S21-5. [PMID: 11068936] CrossrefMedlineGoogle Scholar3. van Hagen PM. Somatostatin receptor expression in clinical immunology. Metabolism. 1996;45:86-7. [PMID: 8769392] CrossrefMedlineGoogle Scholar4. Paran D, Elkayam O, Mayo A, Paran H, Amit M, Yaron M, et al . A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis. 2001;60:888-91. [PMID: 11502617] MedlineGoogle Scholar5. ten Bokum AM, Hofland LJ, de Jong G, Bouma J, Melief MJ, Kwekkeboom DJ, et al . Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest. 1999;29:630-6. [PMID: 10411670] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Royal Prince Alfred Hospital; Camperdown, NSW 2050, AustraliaFlinders Medical Centre and Flinders University; Bedford Park, SA 5042, AustraliaUniversity of Sydney; Newtown, NSW 2006, Australia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPrimary Sjogren’s Syndrome: Current and Prospective TherapiesNew approaches in Sjögren’s syndrome therapySyndrome de Gougerot-Sjögren et orbitopathie basedowienneNeuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin SystemSíndrome de Sjögren. Nuevas perspectivas terapéuticasSomatostatine et scintigraphie des récepteurs de la somatostatine : quel intérêt pour le rhumatologue ?Somatostatin and somatostatin analog scintigraphy: any benefits for rheumatology patients? 5 November 2002Volume 137, Issue 9Page: 777-778KeywordsAutoimmune diseasesCarcinoid tumorFatigueResearch laboratoriesRheumatoid arthritisSarcoidosisSerotoninSomatostatinSwallowingWeight loss ePublished: 5 November 2002 Issue Published: 5 November 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Referência(s)